# A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants

> **NCT04551586** · PHASE1 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ACH-0145228: Immediate Release
- **DRUG:** ACH-0145228: Powder-in-capsule

## Key facts

- **NCT ID:** NCT04551586
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-26
- **Primary completion:** 2020-10-19
- **Final completion:** 2020-10-19
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2021-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04551586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04551586, "A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04551586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*